856 reports of this reaction
1.8% of all ESZOPICLONE reports
#10 most reported adverse reaction
INITIAL INSOMNIA is the #10 most commonly reported adverse reaction for ESZOPICLONE, manufactured by Waylis Therapeutics LLC. There are 856 FDA adverse event reports linking ESZOPICLONE to INITIAL INSOMNIA. This represents approximately 1.8% of all 47,350 adverse event reports for this drug.
Patients taking ESZOPICLONE who experience initial insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INITIAL INSOMNIA is a less commonly reported adverse event for ESZOPICLONE, but still significant enough to appear in the safety profile.
In addition to initial insomnia, the following adverse reactions have been reported for ESZOPICLONE:
The following drugs have also been linked to initial insomnia in FDA adverse event reports:
INITIAL INSOMNIA has been reported as an adverse event in 856 FDA reports for ESZOPICLONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INITIAL INSOMNIA accounts for approximately 1.8% of all adverse event reports for ESZOPICLONE, making it a notable side effect.
If you experience initial insomnia while taking ESZOPICLONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.